Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





RESORCINOL								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 108-46-3; **Chemical Formula:** C6H4(OH)2
H.S. No. 1346
OSHA formerly had no limit for resorcinol. The proposed limit was an 8-hour TWA of 10 ppm and a 15-minute STEL of 20 ppm; the final rule establishes these limits. NIOSH (Ex. 8-47, Table N1) supports the selection of these PELs. The ACGIH has an 8-hour TWA limit of 10 ppm and a TLV-STEL of 20 ppm. Resorcinol occurs in the form of sweet-tasting white crystals that may turn pink on exposure to air and light or on contact with iron.
Resorcinol has been reported to be less toxic by ingestion or skin penetration than either catechol or phenol (von Oettingen 1949 and Koppers Company 1974, both as cited in ACGIH 1986/Ex. 1-3, p. 511). The oral LD(50) in rats is 301 mg/kg (NIOSH 1977i/Ex. 1-1182). Daily six-hour exposures at 8 ppm for two weeks produced no ill effects in rats, guinea pigs, and rabbits. Acute inhalation exposures to a resorcinol-water aerosol at concentrations as high as 7800 mg/m3 for one hour and 2800 mg/m3 for eight hours caused no toxic effects in laboratory animals (Koppers Company 1974, as cited in ACGIH 1986/Ex. 1-3, p. 511).
In humans, the cutaneous application of solutions or salves containing from 3 to 25 percent of this compound may result in local hyperemia, itching, dermatitis, edema, corrosion, and the loss of the superficial layers of the skin. If these damages are severe, they may be associated with some or all of the following effects: enlargement of regional lymph glands, restlessness, methemoglobinemia, cyanosis, convulsions, tachycardia, dyspnea, and death (Patty’s Industrial Hygiene and Toxicology, Vol. 2A, p. 2588, Clayton and Clayton, 1981). An epidemiologic study of rubber workers exposed to a hexamethylene-tetramine-resorcinol rubber system revealed no specific symptoms caused by resorcinol; the concentrations in air were less than 0.3 mg/m3. In another study, there were no reports of irritation or discomfort by workers when concentrations were 10 ppm or less for periods of at least 30 minutes (Patty’s Industrial Hygiene and Toxicology, Vol. 2A, p. 2588, Clayton and Clayton, 1981). Dr. Grace Ziem (Ex. 46) notes that resorcinol exposure is also associated with renal and hepatic effects and with methemoglobinemia.
In the final rule, OSHA is establishing a PEL of 10 ppm TWA and a STEL of 20 ppm for resorcinol. The Agency concludes that this combined limit will protect workers against the significant risks of irritation, methemoglobinemia, and other adverse effects, all material impairments of health that are associated with exposure to this substance at levels above the new PELs.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue